Joseph L Kuti

List of Publications by Year
in descending order

146	4,522	117453	118652
papers	citations	34 h-index	62 g-index

148	148	148	3610
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
2	Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 1725-1730.	1.4	254
3	Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem. Journal of Clinical Pharmacology, 2003, 43, 1116-1123.	1.0	169
4	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2009, 53, 1476-1481.	1.4	114
5	Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 1111-1116.	1.4	110
6	Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clinical Therapeutics, 2004, 26, 1187-1198.	1.1	101
7	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. Journal of Antimicrobial Chemotherapy, 2005, 56, 388-395.	1.3	98
8	Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrobial Agents and Chemotherapy, 2004, 48, 2464-2470.	1.4	96
9	Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Medicine, 2011, 37, 632-638.	3.9	90
10	Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles. Drugs, 2006, 66, 1-14.	4.9	85
11	Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Journal of Critical Care, 2010, 25, 69-77.	1.0	79
12	Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis*1. Clinical Therapeutics, 2004, 26, 493-501.	1.1	77
13	Prolonging Î²-lactam infusion: A review of the rationale and evidence, and guidance for implementation. International Journal of Antimicrobial Agents, 2014, 43, 105-113.	1.1	75
14	Optimal Dosing of Piperacillin-Tazobactam for the Treatment ofPseudomonas aeruginosaInfections: Prolonged or Continuous Infusion?. Pharmacotherapy, 2007, 27, 1490-1497.	1.2	71
15	Optimizing bactericidal exposure for Î²â€‹lactams using prolonged and continuous infusions in the pediatric population. Pediatric Blood and Cancer, 2009, 53, 379-385.	0.8	70
16	Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 1359-1364.	1.4	68
17	In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2014, 58, 874-879.	1.4	65
18	Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young Children. Pediatric Infectious Disease Journal, 2014, 33, 168-173.	1.1	64

#	Article	IF	Citations
19	A guide to therapeutic drug monitoring of Î²â€lactam antibiotics. Pharmacotherapy, 2021, 41, 220-233.	1.2	61
20	In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2012, 56, 202-207.	1.4	58
21	Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. American Journal of Health-System Pharmacy, 2002, 59, 2209-2215.	0.5	54
22	Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagnostic Microbiology and Infectious Disease, 2007, 58, 337-344.	0.8	54
23	Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 5115-5119.	1.4	53
24	Continuous and Prolonged Intravenous Î²-Lactam Dosing: Implications for the Clinical Laboratory. Clinical Microbiology Reviews, 2016, 29, 759-772.	5.7	51
25	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrobial Agents and Chemotherapy, 2016, 60, 1401-1410.	1.4	51
26	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. Clinical Pharmacokinetics, 2017, 56, 617-633.	1.6	47
27	Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients. Journal of Clinical Pharmacology, 2006, 46, 69-75.	1.0	46
28	The Essential Role of Pharmacists in Antimicrobial Stewardship. Infection Control and Hospital Epidemiology, 2016, 37, 753-754.	1.0	45
29	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2020, 75, 1546-1553.	1.3	43
30	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clinical Infectious Diseases, 2019, 68, 1650-1657.	2.9	42
31	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. Surgical Infections, 2019, 20, 55-61.	0.7	37
32	Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagnostic Microbiology and Infectious Disease, 2002, 44, 51-57.	0.8	36
33	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. American Journal of Health-System Pharmacy, 2003, 60, 565-568.	0.5	36
34	Empiric Treatment of Multidrug-ResistantBurkholderia cepaciaLung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy. Pharmacotherapy, 2004, 24, 1641-1645.	1.2	35
35	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. Antimicrobial Agents and Chemotherapy, 2016, 60, 6578-6584.	1.4	35
36	Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2016, 48, 342-343.	1.1	35

#	Article	IF	Citations
37	Making the most of surveillance studies: summary of the OPTAMA Program. Diagnostic Microbiology and Infectious Disease, 2005, 53, 281-287.	0.8	34
38	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagnostic Microbiology and Infectious Disease, 2015, 83, 53-55.	0.8	34
39	Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae,Acinetobacter baumannii, andPseudomonas aeruginosa. Pharmacotherapy, 2004, 24, 8-15.	1.2	32
40	Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1ÂGram/Day Administered as a Rapid 5â€Minute Infusion versus the Standard 30â€Minute Infusion in Healthy Adult Volunteers. Pharmacotherapy, 2013, 33, 266-274.	1.2	32
41	An exploratory analysis of the ability of a cefepime trough concentration greater than 22Âmg/L to predict neurotoxicity. Journal of Infection and Chemotherapy, 2016, 22, 78-83.	0.8	31
42	Use of Monte Carlo simulation to assess the pharmacodynamics of Î²-lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program. Clinical Therapeutics, 2005, 27, 1820-1830.	1.1	30
43	Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. Clinical Infectious Diseases, 2020, 70, 1240-1246.	2.9	29
44	Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New Î²-Lactam Combination Agents. Journal of Clinical Microbiology, 2019, 57, .	1.8	29
45	Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance. Pharmacoeconomics, 2002, 20, 513-528.	1.7	28
46	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. International Journal of Antimicrobial Agents, 2007, 30, 452-457.	1.1	28
47	Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes. Clinical Infectious Diseases, 2014, 59, 905-907.	2.9	28
48	Length of Stay and Hospital Costs Associated with a Pharmacodynamicâ€Based Clinical Pathway for Empiric Antibiotic Choice for Ventilatorâ€Associated Pneumonia. Pharmacotherapy, 2010, 30, 453-462.	1.2	27
49	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. Infection Control and Hospital Epidemiology, 2016, 37, 583-589.	1.0	27
50	Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. International Journal of Antimicrobial Agents, 2006, 28, 62-68.	1.1	26
51	Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infection Control and Hospital Epidemiology, 2016, 37, 215-218.	1.0	26
52	Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem. Pharmacotherapy, 2005, 25, 935-941.	1.2	25
53	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 189-195.	1.3	25
54	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	25

#	Article	IF	Citations
55	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert Opinion on Pharmacotherapy, 2018, 19, 397-408.	0.9	24
56	In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	24
57	Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man. Frontiers in Pharmacology, 2022, 13, 833189.	1.6	24
58	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International Journal of Antimicrobial Agents, 2021, 57, 106299.	1.1	23
59	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Expert Review of Clinical Pharmacology, 2016, 9, 459-476.	1.3	22
60	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. Journal of Clinical Pharmacology, 2017, 57, 712-719.	1.0	22
61	Treatment of Serratia marcescens Meningitis with Prolonged Infusion of Meropenem. Annals of Pharmacotherapy, 2007, 41, 1077-1081.	0.9	21
62	Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries. Infectious Diseases in Clinical Practice, 2015, 23, 318-323.	0.1	21
63	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a â€˜Goldilocksâ€™ window. International Journal of Antimicrobial Agents, 2017, 50, 487-490.	1.1	21
64	Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections. Pharmacoeconomics, 2004, 22, 301-310.	1.7	20
65	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. Journal of Antimicrobial Chemotherapy, 2015, 70, 2064-2067.	1.3	20
66	Tackling Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia in Your ICU: Guidance for Implementing the Guidelines. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 102-115.	0.8	19
67	In Vitro Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure. Antimicrobial Agents and Chemotherapy, 2014, 58, 672-677.	1.4	18
68	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	18
69	In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 7520-7526.	1.4	17
70	Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints. Infection and Drug Resistance, 2018, Volume 11, 783-790.	1.1	17
71	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infectious Diseases and Therapy, 2014, 3, 269-279.	1.8	16
72	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. Diagnostic Microbiology and Infectious Disease, 2018, 91, 294-297.	0.8	16

#	Article	IF	Citations
73	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. Clinical Therapeutics, 2018, 40, 261-269.	1.1	16
74	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2018, 75, 1048-1056.	0.5	15
75	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
76	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). Infectious Diseases and Therapy, 2019, 8, 383-396.	1.8	14
77	Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. Current Opinion in Infectious Diseases, 2020, 33, 482-494.	1.3	14
78	Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. Expert Review of Anti-Infective Therapy, 2020, 18, 705-720.	2.0	14
79	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis â€“ A review of 3 cases. Respiratory Medicine CME, 2010, 3, 146-149.	0.1	13
80	Derivation of Meropenem Dosage in Patients Receiving Continuous Veno-Venous Hemofiltration Based on Pharmacodynamic Target Attainment. Chemotherapy, 2005, 51, 211-216.	0.8	12
81	Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clinical Therapeutics, 2007, 29, 889-899.	1.1	12
82	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2018, 75, e36-e44.	0.5	12
83	Levofloxacin pharmacodynamics against StenotrophomonasÂmaltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. Journal of Antimicrobial Chemotherapy, 2021, 77, 164-168.	1.3	12
84	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2021, 58, 106395.	1.1	12
85	Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. Journal of Antimicrobial Chemotherapy, 2022, 77, 1052-1060.	1.3	12
86	Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2011, 68, 2265-2270.	0.5	11
87	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. BMC Health Services Research, 2018, 18, 932.	0.9	11
88	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
89	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. International Journal of Antimicrobial Agents, 2015, 45, 512-518.	1.1	9
90	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. International Journal of Antimicrobial Agents, 2019, 54, 346-350.	1.1	9

#	Article	IF	Citations
91	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. Clinical Therapeutics, 2020, 42, 606-613.	1.1	9
92	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 9.	1.7	9
93	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clinical Therapeutics, 2019, 41, 2162-2170.	1.1	8
94	In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	8
95	Monte Carlo Simulation Methodologies for Î²â€Łactam/Î²â€Łactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. Journal of Clinical Pharmacology, 2020, 60, 172-180.	1.0	8
96	Imipenem/Cilastatin/Relebactam Alone and in Combination againstPseudomonas aeruginosain theIn VitroPharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
97	Pharmacodynamic Performance of Tigecycline versus Common Intravenous Antibiotics for the Empiric Treatment of Complicated Skin and Skin Structure Infections. Surgical Infections, 2008, 9, 57-66.	0.7	7
98	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. Clinical Therapeutics, 2019, 41, 1453-1462.	1.1	7
99	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). International Journal of Antimicrobial Agents, 2022, 60, 106603.	1.1	7
100	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and â^'20 Â°C. American Journal of Health-System Pharmacy, 2014, 71, 1480-1484.	0.5	6
101	Effects of Clinically Meaningful Concentrations of Antipseudomonal Î²-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. Journal of Clinical Microbiology, 2017, 55, 3502-3512.	1.8	6
102	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. Journal of Pharmacy Practice, 2017, 30, 593-599.	0.5	6
103	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	6
104	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. Journal of Clinical Microbiology, 2019, 57, .	1.8	6
105	In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0216721.	1.4	6
106	In VitroPharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 955-961.	1.4	5
107	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to Î²-Lactam and Fluoroquinolone Concentrations. Journal of Clinical Microbiology, 2019, 57, .	1.8	5
108	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	5

#	Article	IF	Citations
109	Is One Sample Enough? Î²-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
110	Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	5
111	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. International Journal of Antimicrobial Agents, 2016, 47, 247-248.	1.1	4
112	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. Open Forum Infectious Diseases, 2018, 5, ofy206.	0.4	4
113	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
114	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 222-228.	1.4	3
115	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2017, 74, e55-e63.	0.5	3
116	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. International Journal of Antimicrobial Agents, 2019, 53, 698-702.	1.1	3
117	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. Hospital Pharmacy, 2022, 57, 496-503.	0.4	2
118	Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. Connecticut Medicine, 2009, 73, 337-40.	0.2	2
119	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). Open Forum Infectious Diseases, 2021, 8, S646-S646.	0.4	2
120	A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?. Journal of Pharmacy Practice, 2023, 36, 537-541.	0.5	2
121	Cefditoren Pivoxil. Drugs, 2002, 62, 337-338.	4.9	1
122	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. Hospital Pharmacy, 2004, 39, 1069-1075.	0.4	1
123	Reply to Cheng and Chuang. Clinical Infectious Diseases, 2019, 69, 903-904.	2.9	1
124	888. Critical Care Medicine, 2019, 47, 423.	0.4	1
125	Stability of Ertapenem 100 mg/mL at Room Temperature. Canadian Journal of Hospital Pharmacy, 2016, 69, 256-9.	0.1	1
126	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). Open Forum Infectious Diseases, 2020, 7, S670-S670.	0.4	1

#	Article	IF	Citations
127	1103. Minocycline (MIN) Pharmacodynamics (PD) against Stenotrophomonas maltophilia (STM) in a Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2021, 8, S643-S643.	0.4	1
128	Infection and Antibiotic Agents in Bleeding Trauma Patients: A Review of Available Literature. Surgical Infections, 2022, 23, 332-338.	0.7	1
129	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). Open Forum Infectious Diseases, 2021, 8, S635-S635.	0.4	1
130	Influence of automated screening and confirmation of extended-spectrum Î²-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. Journal of Medical Microbiology, 2008, 57, 1147-1151.	0.7	0
131	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. Clinical Medicine Therapeutics, 2009, 1, CMT.S2062.	0.1	0
132	Simplifying Piperacillin/Tazobactam (TZP) Dosing: Pharmacodynamics (PD) of Utilizing 4.5g Doses for Patients With Normal and Impaired Renal Function. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
133	Prevalence and Risk Factors of a Novel Piperacillin/Tazobactam-Nonsusceptible, Î²-Lactam-Pan-Susceptible (TZP-NS/BL-PS) Phenotype in Enterobacteriaceae. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
134	CÃ“MO OPTIMIZAR LA FARMACODINAMIA ANTIMICROBIANA: UNA GUÃ•A PARA UN PROGRAMA DE OPTIMIZACIÃ“N DEL USO DE ANTIMICROBIANOS. Revista MÃ©dica ClÃnica Las Condes, 2016, 27, 625-635.	0.2	0
135	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). Open Forum Infectious Diseases, 2018, 5, S47-S47.	0.4	0
136	1398. Î²-Lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) Based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model. Open Forum Infectious Diseases, 2018, 5, S430-S430.	0.4	0
137	Critique of prevention of pneumococcal disease in high risk adults: A pharmacistâ€based assessment of adult immunization protocols in clinical practice. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 444-445.	0.5	0
138	Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. Surgical Infections, 2021, , .	0.7	0
139	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. Open Forum Infectious Diseases, 2020, 7, S667-S667.	0.4	0
140	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF). Open Forum Infectious Diseases, 2020, 7, S7-S8.	0.4	0
141	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF). Open Forum Infectious Diseases, 2020, 7, S797-S797.	0.4	0
142	112. Impact of Respiratory Viral PCR Panels (RVP) and Serum Procalcitonin (PCT) on Antibiotic Days of Therapy (DOT) in Patients Admitted with Lower Respiratory Tract Infections (LRTI). Open Forum Infectious Diseases, 2020, 7, S70-S70.	0.4	0
143	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model. Open Forum Infectious Diseases, 2020, 7, S667-S667.	0.4	0
144	Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. Connecticut Medicine, 2003, 67, 85-8.	0.2	0

#	Article	IF	Citations
145	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. Open Forum Infectious Diseases, 2021, 8, S147-S148.	0.4	0
146	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against Stenotrophomonas maltophilia (STM). Open Forum Infectious Diseases, 2021, 8, S44-S44.	0.4	0